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jo u rn al ho m epag e: ww w.els evier . c om / lo cat e/ jcc as ePeripartum cardiomyopathy (PPCM) is a rare, but life-threaten-
ing condition that occurs during the peripartum period in previously
healthy women. Recently used diagnostic criteria included an
idiopathic cardiomyopathy presenting with heart failure secondary
to left ventricular systolic dysfunction (left ventricular ejection
fraction <45%) toward the end of pregnancy or in the 5–6 months
following delivery, where no other cause of heart failure was found
[1]. Since it is a diagnosis of exclusion, heterogeneity is a common
element in the pathogenesis of PPCM. Therefore, several theories
have been proposed for the pathophysiological mechanism under-
lying the development of PPCM, including antiangiogenic agents
such as fragmented prolactin [2] and soluble fms-like tyrosine
kinase-1 (sFLT1) [3], autoimmune disorder [4], viral myocarditis [5],
and pregnancy-induced cardiac stress.
Van Spaendonck-Zwarts et al. reported that a subset of PPCM is
an initial manifestation of familial dilated cardiomyopathy (DCM)
[6]. Morales et al. also reported that a proportion of PPCM and
pregnancy-associated cardiomyopathy cases results from a genetic
cause [7]. Those reports more strongly supported the suggestion
that some cases of PPCM may in fact be part of familial DCM.
Actually, titin gene mutations are found to be common in families
with both DCM and PPCM [8]. However, the workshop held by the
US National Heart Lung and Blood Institute and the Ofﬁce of Rare
Diseases concurred that PPCM is a distinct entity, rather than a
clinically silent underlying cardiomyopathy unmasked by the
hemodynamic stresses of pregnancy, because the reported
incidence of PPCM is higher than the incidence of idiopathic
cardiomyopathy [9].
Among pregnant women with underlying heart disease, heart
failure has been described typically at the end of the second
trimester, or after delivery [10]. During pregnancy, especially by
the end of the second trimester, cardiac output increases by 30–
50%, where increase in plasma volume leads to increase in stroke
volume and heart rate. Patients with stenotic lesions or severely
decreased cardiac function cannot tolerate such increased preload,
and therefore are likely to suffer from heart failure. Delivery is
considered another particularly high-risk period because of cardiacDOI of original article: http://dx.doi.org/10.1016/j.jccase.2015.05.002
http://dx.doi.org/10.1016/j.jccase.2015.07.005
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by pain, uterine contractions, bleeding, anesthesia, autotransfusion
from the involuting uterus, and resorption of edema. Those
hemodynamic changes can cause heart failure in pregnant women
with heart disease, including preexisting DCM. However, the onset
of heart failure in PPCM tends to occur in later postpartum
compared to the above timing. This point is one of the reasons why
many of the PPCM cases cannot be explained only by the
hemodynamic stresses for underlying other cardiomyopathy.
PPCM with mutations of titin gene showed a low rate of
recovery (only 2 of 20 PPCM patients showed a full recovery of left
ventricular function) [8]. However, the cardiac function is often
normalized in many PPCM patients. For example, PPCM compli-
cated with pregnancy-associated hypertension showed a better
recovery rate than those without hypertension [11]. From this
point of view, many of PPCM cases must be distinguished from
underlying DCM.
There have been a number of reports in the literature of PPCM in
women with mothers or sisters who had the same diagnosis
without a family history of DCM. In this issue of the journal,
Canpolat et al. reported about four cases of PPCM in the same
family [12]. Interestingly, they showed full recovery of left
ventricular function within a short period. In such cases, other
genetic origins, which are unrelated to DCM, may play a role in the
onset of PPCM.
Several PPCM animal models have been examined. For example,
female mice with a cardiomyocyte-speciﬁc deletion of stat3 were
reported to develop PPCM. In these mice, cardiac cathepsin D
expression and activity is enhanced by increased oxidative stress in
the cardiomyocyte. Cathepsin D activity is associated with the
generation of a cleaved antiangiogenic and proapoptotic 16 kDa
form of the nursing hormone prolactin, which may contribute to
deterioration of PPCM (Fig. 1) [2]. Another mouse model that
lacked cardiac PGC-1a, a powerful regulator of angiogenesis, was
reported to develop profound PPCM [3]. From these results, a
systemic angiogenic imbalance is considered one pathophysiology
for PPCM. Importantly, these PPCM mice models are entirely
rescued by pro-angiogenic therapies. Therefore, genetic factors
related to peripartum angiogenic insufﬁciency have a possibility to
cause the familial PPCM.s reserved.
Fig. 1.
Angiogenic imbalance theory. PPCM, peripartum cardiomyopathy;
MMP, matrix metalloproteinase; BMP-1, bone morphogenic protein-1;
sFLT1, soluble fms-like tyrosine kinase-1.
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ized by high blood pressure and proteinuria, and also known as the
major risk factor of PPCM. Lately, the mechanism of preeclampsia
has been understood further. The placentas of preeclampsia
patients show aplasia of the helicine artery, which induces
increased production of many antiangiogenic factors such as
sFLT1. Antiangiogenic factors cause maternal vascular endothelial
dysfunction and result in elevated blood pressure and renal
dysfunction. Preeclampsia is known to have familial occurrence,
too. Therefore, genetic factors, which relate to both preeclampsia
and PPCM, can exist.
Few data are available with which to formally evaluate any
genetic contribution to susceptibility to PPCM and the studies that
have been published are largely case reports rather than
systematic studies. Lately, next-generation sequencing approach
is used widely to analyze human genes. In the near future, such
technology will allow the evaluation of the common variants,
which contribute to PPCM susceptibility.
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